Mutations in the transmembrane and juxtamembrane domains enhance IL27R transforming activity

Biochemical Journal

Volumn 438, Issue 1, 2011, Pages 155-164

  Lambert, Que T ^a   Pradhan, Anuradha ^a   Roll, J Devon ^a   Reuther, Gary W ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Cytokine receptor; Interleukin 27 receptor (IL27R); Janus kinase signal transducer and activator of transcription (JAK STAT); Mutagenesis; Transformation

Indexed keywords

BCR ABL PROTEIN; CYSTEINE; INTERLEUKIN 27; INTERLEUKIN 27 RECEPTOR; INTERLEUKIN RECEPTOR; JANUS KINASE 1; JANUS KINASE 2; PHENYLALANINE; STAT1 PROTEIN; STAT5 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BLAST CELL; BONE MARROW CELL; CELL STRAIN HEK293; CELL TRANSFORMATION; CONTROLLED STUDY; DIMERIZATION; DISULFIDE BOND; FLOW CYTOMETRY; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; LIGAND BINDING; LYMPHOID CELL; MEMBRANE BINDING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; ANIMALS; BLOTTING, WESTERN; CELL MEMBRANE; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; DIMERIZATION; FLOW CYTOMETRY; FUSION PROTEINS, BCR-ABL; HUMANS; JANUS KINASE 1; KIDNEY; MICE; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; MUTATION; MYELOID CELLS; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, CYTOKINE; RECEPTORS, INTERLEUKIN; SEQUENCE HOMOLOGY, AMINO ACID; STAT TRANSCRIPTION FACTORS;

MURINAE;

EID: 79960800539     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20110351     Document Type: Article

References (50)

1. Malaise, M., Steinbach, D. and Corbacioglu, S. (2009) Clinical implications of c-Kit mutations in acute myelogenous leukemia. Curr. Hematol. Malig. Rep. 4, 77-82
2. Scholl, C., Gilliland, D.G. and Frohling, S. (2008) Deregulation of signaling pathways in acute myeloid leukemia. Semin. Oncol. 35, 336-345
3. Masson, K. and Rönnstrand, L. (2009) Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3. Cell. Signal. 21, 1717-1726
4. Sanz, M., Burnett, A., Lo-Coco, F. and Lowenberg, B. (2009) FLT3 inhibition as a targeted therapy for acute myeloid leukemia. Curr. Opin. Oncol. 21, 594-600
5. Breitenbuecher, F., Schnittger, S., Grundler, R., Markova, B., Carius, B., Brecht, A., Duyster, J., Haferlach, T., Huber, C. and Fischer, T. (2009) Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor. Blood 113, 4074-4077
6. Gari, M., Goodeve, A., Wilson, G., Winship, P., Langabeer, S., Linch, D., Vandenberghe, E., Peake, I. and Reilly, J. (1999) c-Kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. Br. J. Haematol. 105, 894-900
7. Kim, H. G., Kojima, K., Swindle, C. S., Cotta, C. V., Huo, Y., Reddy, V. and Klug, C. A. (2008) FLT3-ITD cooperates with inv(16) to promote progression to acute myeloid leukemia. Blood 111, 1567-1574
8. Ono, R., Nakajima, H., Ozaki, K., Kumagai, H., Kawashima, T., Taki, T., Kitamura, T., Hayashi, Y. and Nosaka, T. (2005) Dimerization of MLL fusion proteins and FLT3 activation synergize to induce multiple-lineage leukemogenesis. J. Clin. Invest. 115, 919-929
9. Schessl, C., Rawat, V. P., Cusan, M., Deshpande, A., Kohl, T. M., Rosten, P. M., Spiekermann, K., Humphries, R. K., Schnittger, S., Kern, W. et al. (2005) The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice. J. Clin. Invest. 115, 2159-2168
10. Zheng, X., Oancea, C., Henschler, R. and Ruthardt, M. (2009) Cooperation between constitutively activated c-Kit signaling and leukemogenic transcription factors in the determination of the leukemic phenotype in murine hematopoietic stem cells. Int. J. Oncol. 34, 1521-1531
11. Arcasoy, M. O., Degar, B. A., Harris, K. W. and Forget, B. G. (1997) Familial erythrocytosis associated with a short deletion in the erythropoietin receptor gene. Blood 89, 4628-4635
12. Arcasoy, M. O., Karayal, A. F., Segal, H. M., Sinning, J. G. and Forget, B. G. (2002) A novel mutation in the erythropoietin receptor gene is associated with familial erythrocytosis. Blood 99, 3066-3069
13. Kralovics, R., Indrak, K., Stopka, T., Berman, B. W., Prchal, J. F. and Prchal, J. T. (1997) Two new EPO receptor mutations: truncated EPO receptors are most frequently associated with primary familial and congenital polycythemias. Blood 90, 2057-2061
14. Percy, M. J., McMullin, M. F., Roques, A. W., Westwood, N. B., Acharya, J., Hughes, A. E., Lappin, T. R. and Pearson, T. C. (1998) Erythrocytosis due to a mutation in the erythropoietin receptor gene. Br. J. Haematol. 100, 407-410
15. Perrotta, S., Cucciolla, V., Ferraro, M., Ronzoni, L., Tramontano, A., Rossi, F., Scudieri, A. C., Borriello, A., Roberti, D., Nobili, B. et al. (2010) EPO receptor gain-of-function causes hereditary polycythemia, alters CD34 cell differentiation and increases circulating endothelial precursors. PLoS ONE 5, e12015
16. Hunter, M. G. and Avalos, B. R. (1999) Deletion of a critical internalization domain in the G-CSFR in acute myelogenous leukemia preceded by severe congenital neutropenia. Blood 93, 440-446
17. Plo, I., Zhang, Y., Le Couedic, J. P., Nakatake, M., Boulet, J. M., Itaya, M., Smith, S. O., Debili, N., Constantinescu, S. N., Vainchenker, W. et al. (2009) An activating mutation in the CSF3R gene induces a hereditary chronic neutrophilia. J. Exp. Med. 206, 1701-1707
18. Hermans, M. H., Antonissen, C., Ward, A. C., Mayen, A. E., Ploemacher, R. E. and Touw, I. P. (1999) Sustained receptor activation and hyperproliferation in response to granulocyte colony-stimulating factor (G-CSF) in mice with a severe congenital neutropenia/acute myeloid leukemia-derived mutation in the G-CSF receptor gene. J. Exp. Med. 189, 683-692
19. Pardanani, A. D., Levine, R. L., Lasho, T., Pikman, Y., Mesa, R. A., Wadleigh, M., Steensma, D. P., Elliott, M. A., Wolanskyj, A. P., Hogan, W. J. et al. (2006) MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 108, 3472-3476
20. Pikman, Y., Lee, B. H., Mercher, T., McDowell, E., Ebert, B. L., Gozo, M., Cuker, A., Wernig, G., Moore, S., Galinsky, I. et al. (2006) MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 3, e270
21. Roll, J. D. and Reuther, G. W. (2010) CRLF2 and JAK2 in B-progenitor acute lymphoblastic leukemia: a novel association in oncogenesis. Cancer Res. 70, 7347-7352
22. Yoda, A., Yoda, Y., Chiaretti, S., Bar-Natan, M., Mani, K., Rodig, S. J., West, N., Xiao, Y., Brown, J. R., Mitsiades, C. et al. (2010) Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. U.S.A. 107, 252-257
23. Reuther, G. W., Lambert, Q. T., Caligiuri, M. A. and Der, C. J. (2000) Identification and characterization of an activating TrkA deletion mutation in acute myeloid leukemia. Mol. Cell. Biol. 20, 8655-8666
24. Reuther, G. W., Lambert, Q. T., Rebhun, J. F., Caligiuri, M. A., Quilliam, L. A. and Der, C. J. (2002) RasGRP4 is a novel Ras activator isolated from acute myeloid leukemia. J. Biol. Chem. 277, 30508-30514
25. Meyer, J., Rhein, M., Schiedlmeier, B., Kustikova, O., Rudolph, C., Kamino, K., Neumann, T., Yang, M., Wahlers, A., Fehse, B. et al. (2007) Remarkable leukemogenic potency and quality of a constitutively active neurotrophin receptor, ΔTrkA. Leukemia 21, 2171-2180 (Pubitemid 47423807)
26. + cells, allowing nerve growth factor-induced expansion. Proc. Natl. Acad. Sci. U.S.A. 102, 4016-4021
27. Watanabe-Okochi, N., Oki, T., Komeno, Y., Kato, N., Yuji, K., Ono, R., Harada, Y., Harada, H., Hayashi, Y., Nakajima, H. et al. (2009) Possible involvement of RasGRP4 in leukemogenesis. Int. J. Hematol. 89, 470-481
28. Pradhan, A., Lambert, Q. T. and Reuther, G. W. (2007) Transformation of hematopoietic cells and activation of JAK2-V617F by IL-27R, a component of a heterodimeric type I cytokine receptor. Proc. Natl. Acad. Sci. U.S.A. 104, 18502-18507
29. Pradhan, A., Lambert, Q. T., Griner, L. N. and Reuther, G. W. (2010) Activation of JAK2-V617F by components of heterodimeric cytokine receptors. J. Biol. Chem. 285, 16651-16663
30. Pflanz, S., Hibbert, L., Mattson, J., Rosales, R., Vaisberg, E., Bazan, J. F., Phillips, J. H., McClanahan, T. K., de Waal Malefyt, R. and Kastelein, R. A. (2004) WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J. Immunol. 172, 2225-2231
31. Hunter, C. A. (2005) New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat. Rev. Immunol. 5, 521-531
32. Yoshida, H. and Miyazaki, Y. (2008) Regulation of immune responses by interleukin-27. Immunol. Rev. 226, 234-247
33. Villarino, A. V., Huang, E. and Hunter, C. A. (2004) Understanding the pro- and anti-inflammatory properties of IL-27. J. Immunol. 173, 715-720
34. + T cells. J. Immunol. 173, 3871-3877
35. + T cells through Stat1-dependent and -independent mechanisms. Proc. Natl. Acad. Sci. U.S.A. 100, 15047-15052
36. Seita, J., Asakawa, M., Ooehara, J., Takayanagi, S., Morita, Y., Watanabe, N., Fujita, K., Kudo, M., Mizuguchi, J., Ema, H. et al. (2008) Interleukin-27 directly induces differentiation in hematopoietic stem cells. Blood 111, 1903-1912 (Pubitemid 351451499)
37. Koh, E. Y., Chen, T. and Daley, G. Q. (2002) Novel retroviral vectors to facilitate expression screens in mammalian cells. Nucleic Acids Res. 30, e142
38. Muller, A. J., Young, J. C., Pendergast, A. M., Pondel, M., Landau, N. R., Littman, D. R. and Witte, O. N. (1991) BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias. Mol. Cell. Biol. 11, 1785-1792
39. Gordon, G. M., Lambert, Q. T., Daniel, K. G. and Reuther, G. W. (2010) Transforming JAK1 mutations exhibit differential signalling, FERM domain requirements and growth responses to interferon-γ. Biochem. J. 432, 255-265
40. Tefferi, A. (2009) Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1. J. Cell Mol. Med. 13, 215-237
41. Milone, J. H. and Enrico, A. (2009) Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Leuk. Lymphoma 50 (Suppl. 2), 9-15
42. Sprecher, C. A., Grant, F. J., Baumgartner, J. W., Presnell, S. R., Schrader, S. K., Yamagiwa, T., Whitmore, T. E., O'Hara, P. J. and Foster, D. F. (1998) Cloning and characterization of a novel class I cytokine receptor. Biochem. Biophys. Res. Commun. 246, 82-90
43. Takeda, A., Hamano, S., Yamanaka, A., Hanada, T., Ishibashi, T., Mak, T. W., Yoshimura, A. and Yoshida, H. (2003) Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. J. Immunol. 170, 4886-4890 (Pubitemid 36554716)
44. Hashimoto, Y., Kurita, M., Aiso, S., Nishimoto, I. and Matsuoka, M. (2009) Humanin inhibits neuronal cell death by interacting with a cytokine receptor complex or complexes involving CNTF receptor α/WSX-1/gp130. Mol. Biol. Cell 20, 2864-2873
45. Lu, X., Gross, A. W. and Lodish, H. F. (2006) Active conformation of the erythropoietin receptor: random and cysteine-scanning mutagenesis of the extracellular juxtamembrane and transmembrane domains. J. Biol. Chem. 281, 7002-7011
46. Chen, E., Beer, P. A., Godfrey, A. L., Ortmann, C. A., Li, J., Costa-Pereira, A. P., Ingle, C. E., Dermitzakis, E. T., Campbell, P. J. and Green, A. R. (2010) Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling. Cancer Cell 18, 524-535
47. Kovacic, B., Stoiber, D., Moriggl, R., Weisz, E., Ott, R. G., Kreibich, R., Levy, D. E., Beug, H., Freissmuth, M. and Sexl, V. (2006) STAT1 acts as a tumor promoter for leukemia development. Cancer Cell 10, 77-87
48. Collins-Underwood, J. R. and Mullighan, C. G. (2011) Genomic profiling of high-risk acute lymphoblastic leukemia. Leukemia 24, 1676-1685
49. Zhang, J., Mullighan, C., Harvey, R., Carroll, W. L., Chen, I. M. L., Devidas, M., Larsen, E., Edmonson, M., Buetow, K., Gerhard, D. S. et al. (2011) Lack of somatic sequence mutations in protein tyrosine kinase genes other than the JAK kinase family in high risk B-precursor childhood acute lymphoblastic leukemia (ALL): a report from the Children's Oncology Group (COG) High-Risk (HR) ALL TARGET project. 53rd ASH Annual Meeting, 10-13 December 2011, San Diego, U.S.A, Abstract 2752
50. Hirokawa, T., Boon-Chieng, S. and Mitaku, S. (1998) SOSUI: classification and secondary structure prediction system for membrane proteins. Bioinformatics 14, 378-379 (Pubitemid 28393805)